SG11201600110RA - Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation - Google Patents

Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation

Info

Publication number
SG11201600110RA
SG11201600110RA SG11201600110RA SG11201600110RA SG11201600110RA SG 11201600110R A SG11201600110R A SG 11201600110RA SG 11201600110R A SG11201600110R A SG 11201600110RA SG 11201600110R A SG11201600110R A SG 11201600110RA SG 11201600110R A SG11201600110R A SG 11201600110RA
Authority
SG
Singapore
Prior art keywords
anticholinergic
corticosteroid
adrenergic
inhalation
beta
Prior art date
Application number
SG11201600110RA
Other languages
English (en)
Inventor
Rossella Musa
Irene Pasquali
Azita Askey-Sarvar
Francesca Schiaretti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51292914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201600110R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of SG11201600110RA publication Critical patent/SG11201600110RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11201600110RA 2013-07-11 2014-07-10 Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation SG11201600110RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13176114 2013-07-11
EP13194763 2013-11-28
PCT/EP2014/064824 WO2015004243A1 (en) 2013-07-11 2014-07-10 Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation

Publications (1)

Publication Number Publication Date
SG11201600110RA true SG11201600110RA (en) 2016-02-26

Family

ID=51292914

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201600110RA SG11201600110RA (en) 2013-07-11 2014-07-10 Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation

Country Status (34)

Country Link
US (2) US9402825B2 (zh)
EP (3) EP3019153B1 (zh)
JP (1) JP6426167B2 (zh)
KR (2) KR102275904B1 (zh)
CN (1) CN105338960B (zh)
AU (1) AU2014289185B2 (zh)
BR (1) BR112015030914B1 (zh)
CA (1) CA2917752C (zh)
CL (1) CL2016000028A1 (zh)
CY (2) CY1120806T1 (zh)
DK (2) DK3019153T3 (zh)
EA (1) EA029125B1 (zh)
ES (2) ES2867552T3 (zh)
GE (1) GEP20186853B (zh)
HK (1) HK1218712A1 (zh)
HR (2) HRP20182008T1 (zh)
HU (2) HUE039827T2 (zh)
IL (1) IL243507A0 (zh)
LT (2) LT3409270T (zh)
MX (1) MX2016000290A (zh)
MY (1) MY176176A (zh)
NZ (1) NZ715797A (zh)
PE (2) PE20212110A1 (zh)
PH (1) PH12016500043B1 (zh)
PL (2) PL3409270T3 (zh)
PT (1) PT3019153T (zh)
RS (2) RS57799B1 (zh)
SA (1) SA516370373B1 (zh)
SG (1) SG11201600110RA (zh)
SI (2) SI3409270T1 (zh)
TN (1) TN2016000007A1 (zh)
TW (1) TWI642450B (zh)
UA (1) UA116907C2 (zh)
WO (1) WO2015004243A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104055765B (zh) 2009-12-23 2016-11-23 奇斯药制品公司 用于copd的联合治疗
PT3527197T (pt) * 2012-01-25 2022-10-26 Chiesi Farm Spa Formulação de um pó seco compreendendo um corticosteroide e um adrenérgico beta para administração por inalação
EA029125B1 (ru) * 2013-07-11 2018-02-28 Кьези Фармасьютичи С.П.А. Сухая порошковая композиция, содержащая антихолинергический агент, кортикостероид и бета-адренергический агент, для введения путем ингаляции
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
TR201407010A2 (tr) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formülasyonları.
JP6600961B2 (ja) * 2015-03-30 2019-11-06 ブラザー工業株式会社 表示制御装置、表示制御方法及び記憶媒体
BR112017023351B1 (pt) * 2015-05-01 2023-11-28 Board Of Regents, The University Of Texas System Composição farmacêutica e uso da composição farmacêutica
EA037716B1 (ru) 2015-11-16 2021-05-13 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения сухой порошковой композиции, содержащей антихолинергическое средство, кортикостероид и бета-адренергическое средство, порошковая композиция, ингалятор, применение сухой порошковой композиции для профилактики и/или лечения воспалительного и/или обструктивного заболевания дыхательных путей
SG10201912090UA (en) 2015-11-16 2020-02-27 Chiesi Farm Spa A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
CA3131129A1 (en) 2016-11-10 2018-05-17 Medisca Pharmaceutique Inc. Adaptor for use in methods for compounding compositions
MX2019012930A (es) * 2017-05-11 2020-01-14 Chiesi Farm Spa Proceso para preparacion de una formulacion de polvo seco que incluye un anticolinergico, un corticosteroide y un beta-adrenergico.
BR112019023378A2 (pt) * 2017-05-11 2020-06-16 Chiesi Farmaceutici S.P.A. Processo para preparar uma formulação em pó para inalação para uso em um inalador de pó seco
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
EP4034079A1 (en) * 2019-09-24 2022-08-03 Chiesi Farmaceutici S.p.A. Novel carrier particles for dry powder formulations for inhalation
US20240050382A1 (en) * 2022-08-11 2024-02-15 De Motu Cordis Pty Ltd Inhalable Epinephrine Formulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2192866T3 (es) 1998-11-13 2003-10-16 Jago Res Ag Polvo seco para inhalacion.
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
CA2413692C (en) * 2000-06-27 2011-10-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
ES2708961T3 (es) * 2000-11-30 2019-04-12 Vectura Ltd Composiciones farmacéuticas para inhalación
SI1386630T1 (sl) 2002-07-31 2006-10-31 Chiesi Farma Spa Inhalator za prasek
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
CN104055765B (zh) 2009-12-23 2016-11-23 奇斯药制品公司 用于copd的联合治疗
WO2011076841A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
TR201000681A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
ES2675575T3 (es) 2010-04-01 2018-07-11 Chiesi Farmaceutici S.P.A. Proceso para preparar partículas vehículo para polvos secos para inhalación
WO2011131663A1 (en) 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. "process for providing particles with reduced electrostatic charges"
BR112012032330A2 (pt) * 2010-06-22 2016-11-08 Chiesi Farma Spa formulação em pó seco inalável, uso de uma formulação em pó seco, inalador de pó seco e embalagem
PT3527197T (pt) 2012-01-25 2022-10-26 Chiesi Farm Spa Formulação de um pó seco compreendendo um corticosteroide e um adrenérgico beta para administração por inalação
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
EA029125B1 (ru) * 2013-07-11 2018-02-28 Кьези Фармасьютичи С.П.А. Сухая порошковая композиция, содержащая антихолинергический агент, кортикостероид и бета-адренергический агент, для введения путем ингаляции

Also Published As

Publication number Publication date
HUE053957T2 (hu) 2021-08-30
PT3019153T (pt) 2018-12-04
MY176176A (en) 2020-07-24
SI3409270T1 (sl) 2021-07-30
KR20160029797A (ko) 2016-03-15
HK1218712A1 (zh) 2017-03-10
NZ715797A (en) 2020-06-26
PL3409270T3 (pl) 2021-08-09
KR20210075217A (ko) 2021-06-22
EA201690006A1 (ru) 2016-07-29
PL3019153T3 (pl) 2019-02-28
EP3409270B1 (en) 2021-02-24
DK3409270T3 (da) 2021-04-26
TN2016000007A1 (en) 2017-07-05
JP2016523950A (ja) 2016-08-12
ES2867552T3 (es) 2021-10-20
EP3569222A1 (en) 2019-11-20
LT3409270T (lt) 2021-07-26
CL2016000028A1 (es) 2016-08-05
EP3019153A1 (en) 2016-05-18
TWI642450B (zh) 2018-12-01
GEP20186853B (en) 2018-05-25
LT3019153T (lt) 2018-11-26
US9402825B2 (en) 2016-08-02
KR102275904B1 (ko) 2021-07-13
PE20212110A1 (es) 2021-11-04
IL243507A0 (en) 2016-02-29
US20150017248A1 (en) 2015-01-15
HRP20182008T1 (hr) 2019-01-25
US9808422B2 (en) 2017-11-07
MX2016000290A (es) 2016-04-13
CA2917752A1 (en) 2015-01-15
CY1123937T1 (el) 2022-05-27
EA029125B1 (ru) 2018-02-28
CY1120806T1 (el) 2019-12-11
PH12016500043A1 (en) 2016-03-28
SI3019153T1 (sl) 2018-12-31
AU2014289185A1 (en) 2016-02-04
PH12016500043B1 (en) 2016-03-28
BR112015030914A2 (zh) 2017-07-25
UA116907C2 (uk) 2018-05-25
WO2015004243A1 (en) 2015-01-15
RS57799B1 (sr) 2018-12-31
PE20160372A1 (es) 2016-05-19
HRP20210704T1 (hr) 2021-06-11
CA2917752C (en) 2022-05-03
US20160263027A1 (en) 2016-09-15
SA516370373B1 (ar) 2017-10-11
RS61652B1 (sr) 2021-04-29
CN105338960B (zh) 2019-06-04
EP3019153B1 (en) 2018-09-05
TW201536352A (zh) 2015-10-01
AU2014289185B2 (en) 2019-05-23
CN105338960A (zh) 2016-02-17
DK3019153T3 (en) 2018-11-19
ES2699986T3 (es) 2019-02-13
HUE039827T2 (hu) 2019-02-28
EP3409270A1 (en) 2018-12-05
JP6426167B2 (ja) 2018-11-21
BR112015030914B1 (pt) 2023-04-04

Similar Documents

Publication Publication Date Title
HRP20182008T1 (hr) Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom
HRP20181550T1 (hr) Formulacija suhog praška koja sadrži kortikosteroid i beta-adrenergik za davanje inhalacijom
PT3409270T (pt) Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação